(Press-News.org) OAKLAND, Calif., Sept. 20, 2013 — Digoxin, a drug commonly used to treat heart conditions, was associated with a 72 percent higher rate of death among adults with newly diagnosed systolic heart failure, according to a Kaiser Permanente study that appears in the current online issue of Circulation: Cardiovascular Quality and Outcomes.
Digoxin is a drug derived from digitalis, a plant that has been used for more than 200 years to treat heart failure.
"These findings suggest that the use of digoxin should be reevaluated for the treatment of systolic heart failure in contemporary clinical practice" said Alan S. Go, MD, senior author of the study and research scientist at the Kaiser Permanente Division of Research.
The results of this study contrast with the findings of a randomized trial by the Digitalis Investigation Group conducted between 1991 and 1993, which showed that digoxin did not lower mortality among therapy patients with systolic heart failure, or, a malfunction in the way the left ventricle of the heart pumps blood. Following the group's study, professional societies issued clinical guidelines endorsing the use of digoxin for patients with systolic dysfunction.
The current study was conducted among 2,891 adults within Kaiser Permanente in Northern California who had newly diagnosed systolic heart failure between 2006 and 2008 and no prior digoxin use. Eighteen percent of the participants initiated digoxin during the study period.
Researchers followed the patients through December 31, 2010, to evaluate the effectiveness and safety of digoxin therapy. They found that digoxin use was associated with higher mortality but no significant difference in the risk of heart failure hospitalization.
There were a total of 801 deaths (737 off digoxin and 64 on digoxin). After adjustment for potential confounders, digoxin use was associated with a 72 percent higher relative rate of death.
There were 1,723 hospitalizations for heart failure overall (1,596 off digoxin, 127 on digoxin). However, after adjustment for potential confounders, digoxin use was not significantly associated with hospitalization for heart failure.
"Our community-based study population is more likely to represent patients with systolic heart failure in the modern era with regard to pathogenesis and treatment patterns," Dr. Go said. "Therefore, our results may more accurately represent the outcomes expected with digoxin for patients with systolic heart failure in typical present-day practices. As with all medication, treatment, or therapy plans, care decisions should always be made by physicians and their patients working together, with the patient's particular care needs and goals in mind."
###
Other authors on the study include James V. Freeman, MD, MPH of Yale University School of Medicine; Mark A. Hlatky, MD of the Stanford University School of Medicine; and Jingrong Yang, MA, and Sue Hee Sung, MPH, of the Division of Research, Kaiser Permanente Northern California.
About the Kaiser Permanente Division of Research
The Kaiser Permanente Division of Research (DOR) conducts, publishes and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and the society at large. It seeks to understand the determinants of illness and well-being and to improve the quality and cost-effectiveness of health care. Currently, DOR's 600-plus staff is working on more than 250 epidemiological and health services research projects. For more information, visit http://www.dor.kaiser.org.
About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, our mission is to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve more than 9.1 million members in nine states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to kp.org/newscenter.
Digoxin use associated with higher risk of death for patients diagnosed with heart failure
2013-09-20
ELSE PRESS RELEASES FROM THIS DATE:
Scripps Research Institute study explores barriers to HIV vaccine response
2013-09-20
LA JOLLA, CA -- Researchers at The Scripps Research Institute (TSRI) discovered that an antibody that binds and neutralizes HIV likely also targets the body's own "self" proteins. This finding could complicate the development of HIV vaccines designed to elicit this protective antibody, called 4E10, and others like it, as doing so might be dangerous or inefficient.
"We developed two new mouse models that allow us to visualize the fate of the rare B cells that can see HIV and we thought could be stimulated by vaccines to produce neutralizing antibodies -- the type of antibodies ...
The higher the better?
2013-09-20
High-intensity exercise is shown to be protective against coronary heart disease (CHD) and is well known as a popular and time-saving approach to getting fit. But what about people who already have heart disease? Previously, these patients were told to exercise, but only at a moderate intensity to protect their hearts. More recently, however, researchers have found that high-intensity exercise is very beneficial for these patients. But how intense should these sessions actually be?
A new study from the K. G. Jebsen -- Center of Exercise in Medicine at the Norwegian University ...
Building the best brain: U-M researchers show how brain cell connections get cemented early in life
2013-09-20
ANN ARBOR, Mich. -- When we're born, our brains aren't very organized. Every brain cell talks to lots of other nearby cells, sending and receiving signals across connections called synapses.
But as we grow and learn, things get a bit more stable. The brain pathways that will serve us our whole lives start to organize, and less-active, inefficient synapses shut down.
But why and how does this happen? And what happens when it doesn't go normally? New research from the University of Michigan Medical School may help explain.
In a new paper in Nature Neuroscience, a ...
Gap closed in the genetic map of kingdom fungi
2013-09-20
Today, the genomes of more than 250 fungi have been sequenced. Among the basal filamentous ascomycetes – a group of ascomycetes that includes e.g. truffles and morels – only one representative has been analysed so far: the truffle Tuber melanosporum. "With 125 million base pairs, the truffle genome is unusually big, yet it is coding for relatively few genes, namely some 7,500," says Minou Nowrousian from the Department of General and Molecular Botany. "Until now, it was not clear whether this is typical of basal filamentous ascomycetes or whether it is caused by the truffle's ...
Lifestyle influences metabolism via DNA methylation
2013-09-20
In the course of life, aging processes, environmental influences and lifestyle factors such as smoking or diet induce biochemical alterations to the DNA. Frequently, these lead to DNA methylation, a process in which methyl groups are added to particular DNA segments, without changing the DNA sequence. Such processes can influence gene function and are known as epigenetics. Scientists of the Institute of Genetic Epidemiology (IGE) and the Research Unit Molecular Epidemiology (AME) at Helmholtz Zentrum München are seeking to determine what association exists between these ...
New rat genus discovered in the birthplace of the theory of evolution
2013-09-20
A prominent tuft of spiny hair on the back, a white tail tip and three pairs of teats represent the unique set of characteristics describing a new genus of rat which has been discovered in the Moluccan province of Indonesia. This region had a profound influence on the British Naturalist Alfred Russell Wallace who independently developed the theory of evolution alongside Charles Darwin. The international team of zoologists was led by the Museum Zoologicum Bogoriense in Indonesia and the Center for Macroecology, Evolution and Climate at the University of Copenhagen.
One ...
Getting rid of unwanted visitors
2013-09-20
The digestive systems of all animals contain a large number of different bacteria. Humans are no exception and our intestines provide warmth, shelter and food to a vast range of unicellular organisms, many of which are either beneficial to their hosts or at least cause no ill effects other than consuming some of the food we ingest. However, several species have been associated with disease. Among them is Helicobacter pylori, which may play a part in causing chronic gastritis and gastric ulcers.
An ancient colonizer recently discovered
Helicobacter pylori was only discovered ...
Crucial new insight into the secrets of Nobel Prize-winning pump
2013-09-20
The story of the sodium-potassium pump has strong ties to Denmark. In 1997, the Danish scientist Jens Chr. Skou received the Nobel Prize in Chemistry for his discovery, and over the years, research on the pump has remained a strong focus area at Aarhus University. In 2007, the joint efforts of various research teams at Aarhus University led to the description of the structure of the potassium-bound state of the pump - now, Danish researchers have also described the other state of the pump; the sodium-bound state. The results were recently published in the journal Science.
The ...
New research on inherited herpesvirus may have implications for transplantation
2013-09-20
Up to half a million people in Britain today may not know it, but in their genetic material they carry a particular form of herpesvirus 6 inherited from a parent.
The study from the world-renowned Department of Genetics at the University of Leicester, is funded principally by the Medical Research Council (MRC), and published in the journal Nucleic Acids Research.
The research led by Dr Nicola Royle, Senior Lecturer in Genetics, has identified a mechanism by which the inherited herpesvirus 6 can escape from the chromosome and may be able to reactivate under certain ...
Elvitegravir fixed combination in HIV: Lesser benefit for treatment-naive patients
2013-09-20
The drug combination of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil (elvitegravir fixed combination, trade name: Stribild) has been approved in Germany since May 2013 for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether an added benefit is proven for this combination over the current standard therapy.
This is not the case: ...